Fox Allan M. 4

4 · REGENXBIO Inc. · Filed Dec 27, 2021

Form 4

Period: 2021-12-22

Director

Transactions

Sale
Common Stock
2021-12-23$35.85/sh−6,323$226,664→ 1,529,981 total(indirect: By LLC)
Sale
Common Stock
2021-12-23$34.92/sh−44,908$1,568,120→ 1,536,304 total(indirect: By LLC)
Sale
Common Stock
2021-12-22$34.40/sh−61,638$2,120,575→ 1,581,212 total(indirect: By LLC)

Holdings

Footnotes (4)

[F1]This transaction was executed in multiple trades at prices ranging from $34.01 to $34.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F2]The reporting person disclaims beneficial ownership of such shares except to the extent of his indirect pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
[F3]This transaction was executed in multiple trades at prices ranging from $34.75 to $35.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]This transaction was executed in multiple trades at prices ranging from $35.75 to $36.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file